研究目的
To develop a fibrinogen biosensing platform based on plasmonic gallium nanoparticles and aminosilane-titanate antibody trapping for rapid detection of key biomolecules as indicators of health states.
研究成果
The developed biosensing platform can differentiate between three states of fibrinogen concentration, offering potential for fast screening of diseases related to abnormal fibrinogen levels. Further improvements in GaNPs size homogeneity could enhance device reliability.
研究不足
The platform requires further progress for color shifts identifiable by the naked eye and improvement in sample homogeneity to minimize statistical errors during biosensing.
1:Experimental Design and Method Selection:
The study involved the deposition of Ga nanoparticles on Si substrates using Joule-effect thermal evaporation, followed by biofunctionalization with aminosilane-titanate thin hybrid layers via a sol-gel route. Specific immunoglobulins were immobilized to sensitize the platform to fibrinogen.
2:Sample Selection and Data Sources:
Si substrates were used for GaNPs deposition. Fibrinogen solutions in phosphate buffered saline were used for detection assays.
3:List of Experimental Equipment and Materials:
Edwards E306 vertical system for GaNPs deposition, FEI XL30-SFEG system for SEM, M-2000? system from JA Woollam Co. for spectroscopic ellipsometry.
4:Experimental Procedures and Operational Workflow:
The process included GaNPs deposition, aminosilanization, IgG immobilization, surface blocking with BSA, and fibrinogen detection monitored by ellipsometry.
5:Data Analysis Methods:
Spectroscopic ellipsometry was used to monitor plasmon wavelength changes. SEM and FTIR were used for morphological and spectroscopic characterization.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容